Defendant
1 case as defendant.
Bio-Thera Solutions, Ltd. (commonly known as Bio-Thera) is a commercial-stage biopharmaceutical company headquartered in Guangzhou, China, and founded in 2003. It is a public company listed on the STAR Market of the Shanghai Stock Exchange (688177.SH). As of 2022, the company had 1,189 employees, with revenue in 2025 reported at 935.22 million CNY.
Bio-Thera is dedicated to researching and developing novel therapeutics for cancer, autoimmune, cardiovascular, and eye diseases, alongside biosimilars for existing branded biologics. Their product portfolio includes approved biosimilars such as QLETLI® (adalimumab) and BETAGRIN® (bevifibatide citrate) Injection in China, TOFIDENCE® (tocilizumab) and AVZIVI® (bevacizumab-tnjn) in the US, EU, and China, and STARJEMZA® and USYMRO® (ustekinumab) in the US and EU, respectively. They also have a pipeline of innovative candidates, including antibody-drug conjugates (ADCs) and immuno-oncology programs.
In terms of patent litigation, Bio-Thera appears as a defendant in the single tracked case. This posture suggests the company is primarily an operating company that develops and commercializes its own biopharmaceutical products, defending against patent challenges.
The single tracked case, Janssen et al. v. Bio-Thera, was filed on February 27, 2026, in the U.S. District Court for the District of Delaware, where Bio-Thera is listed as a defendant. This case likely pertains to patent disputes surrounding one of their commercialized or pipeline products. Notably, Bio-Thera's STARJEMZA® (ustekinumab) biosimilar references STELARA®, a product of Janssen.
This active case involves a declaratory judgment of infringement of US Patent 12122824, brought by Janssen and Centocor Biologic LLC, likely against Bio-Thera in the context of an aBLA for BAT2506.